SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 5,244 call options on the stock. This is an increase of 75% compared to the average daily volume of 3,003 call options.
Institutional Investors Weigh In On SELLAS Life Sciences Group
A number of hedge funds have recently bought and sold shares of the business. Armistice Capital LLC bought a new position in SELLAS Life Sciences Group during the 4th quarter worth approximately $869,000. Opus Capital Group LLC lifted its holdings in shares of SELLAS Life Sciences Group by 291.3% in the 4th quarter. Opus Capital Group LLC now owns 135,000 shares of the company's stock worth $143,000 after purchasing an additional 100,500 shares during the last quarter. Finally, Anson Funds Management LP bought a new stake in shares of SELLAS Life Sciences Group in the 1st quarter worth approximately $4,881,000. Institutional investors and hedge funds own 17.38% of the company's stock.
SELLAS Life Sciences Group Trading Up 2.1 %
Shares of NASDAQ SLS traded up $0.03 during trading on Wednesday, reaching $1.45. The company had a trading volume of 1,217,537 shares, compared to its average volume of 1,361,286. The stock has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.09. SELLAS Life Sciences Group has a twelve month low of $0.50 and a twelve month high of $1.91. The stock has a market capitalization of $83.75 million, a PE ratio of -1.32 and a beta of 2.11.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that SELLAS Life Sciences Group will post -0.75 EPS for the current year.
About SELLAS Life Sciences Group
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Featured Stories
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
